IDH1 and glioma: In human patients, IDH1/2 mutations in glioma or AML define distinct patient subgroups associated with CIMP.80, 81 DNA hypermethylation induced by 2-HG is reversible, and therefore represents a viable therapeutic target in IDH1/2-mutant cancers.17